2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 71, n° 6
pages 1093-1101 (décembre 2014)
Doi : 10.1016/j.jaad.2014.09.018
accepted : 8 September 2014
Original Articles

Mortality in women with pregnancy-associated malignant melanoma

Anna L.V. Johansson, MSc a, , Therese M-L. Andersson, PhD a, Anna Plym, MSc a, Gustav J. Ullenhag, MD, PhD b, Henrik Møller, Dr Med c, Mats Lambe, MD, PhD a, d
a Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 
b Department of Radiology, Oncology, and Radiation Science, Section of Oncology, Uppsala University, Uppsala, Sweden 
c Cancer Epidemiology and Population Health, King's College London, London, United Kingdom 
d Regional Cancer Center, Uppsala, Sweden 

Reprint requests: Anna L. V. Johansson, MSc, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-17177 Stockholm, Sweden.

Malignant melanoma (MM) is one of the most common malignancies in young women. It remains debated whether a MM diagnosed during pregnancy or lactation has a worse prognosis.


We sought to examine mortality in women with pregnancy-associated MM (PAMM) (diagnosed during pregnancy and up to 2-years postpartum).


This was a population-based cohort study based on information retrieved from the Swedish Cancer and Multi-Generation Registers. Hazard ratios with 95% confidence intervals adjusted for age, period, education, parity, and tumor location were estimated.


In total, 6857 women and girls aged 15 to 44 years with a diagnosis of cutaneous MM between 1963 and 2009 were identified. Of these, 1019 cases were classified as PAMM. The cause-specific mortality did not differ between PAMM and MM not diagnosed near childbirth (adjusted hazard ratio 1.09, 95% confidence interval 0.83-1.42).


Information on stage at diagnosis was available only for a subset of patients


Overall, the cause-specific mortality in women and girls with PAMM did not differ from that in women and girls with non-PAMM. The current findings do not provide evidence of an adverse prognostic influence of pregnancy or a recent birth.

The full text of this article is available in PDF format.

Key words : malignant melanoma, mortality, pregnancy, stage, survival, Sweden

Abbreviations used : CI, FPM, HR, MM, PAMM

 Supported by a grant from Karolinska Institutet Funds.
 Conflicts of interest: None declared.

© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline